Cargando…
Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials
The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. To facilitate immunogen design, it is important to characterize clusters of commonly targeted T-cell epitopes across different HIV clades. To address this, we examined 39 HIV-1 clade C infected indivi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192159/ https://www.ncbi.nlm.nih.gov/pubmed/22022524 http://dx.doi.org/10.1371/journal.pone.0026096 |
_version_ | 1782213722767360000 |
---|---|
author | Zembe, Lycias Burgers, Wendy A. Jaspan, Heather B. Bekker, Linda-Gail Bredell, Helba Stevens, Gwynneth Gilmour, Jill Cox, Josephine H. Fast, Patricia Hayes, Peter Vardas, Eftyhia Williamson, Carolyn Gray, Clive M. |
author_facet | Zembe, Lycias Burgers, Wendy A. Jaspan, Heather B. Bekker, Linda-Gail Bredell, Helba Stevens, Gwynneth Gilmour, Jill Cox, Josephine H. Fast, Patricia Hayes, Peter Vardas, Eftyhia Williamson, Carolyn Gray, Clive M. |
author_sort | Zembe, Lycias |
collection | PubMed |
description | The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. To facilitate immunogen design, it is important to characterize clusters of commonly targeted T-cell epitopes across different HIV clades. To address this, we examined 39 HIV-1 clade C infected individuals for IFN-γ Gag-specific T-cell responses using five sets of overlapping peptides, two sets matching clade C vaccine candidates derived from strains from South Africa and China, and three peptide sets corresponding to consensus clades A, B, and D sequences. The magnitude and breadth of T-cell responses against the two clade C peptide sets did not differ, however clade C peptides were preferentially recognized compared to the other peptide sets. A total of 84 peptides were recognized, of which 19 were exclusively from clade C, 8 exclusively from clade B, one peptide each from A and D and 17 were commonly recognized by clade A, B, C and D. The entropy of the exclusively recognized peptides was significantly higher than that of commonly recognized peptides (p = 0.0128) and the median peptide processing scores were significantly higher for the peptide variants recognized versus those not recognized (p = 0.0001). Consistent with these results, the predicted Major Histocompatibility Complex Class I IC(50) values were significantly lower for the recognized peptide variants compared to those not recognized in the ELISPOT assay (p<0.0001), suggesting that peptide variation between clades, resulting in lack of cross-clade recognition, has been shaped by host immune selection pressure. Overall, our study shows that clade C infected individuals recognize clade C peptides with greater frequency and higher magnitude than other clades, and that a selection of highly conserved epitope regions within Gag are commonly recognized and give rise to cross-clade reactivities. |
format | Online Article Text |
id | pubmed-3192159 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-31921592011-10-21 Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials Zembe, Lycias Burgers, Wendy A. Jaspan, Heather B. Bekker, Linda-Gail Bredell, Helba Stevens, Gwynneth Gilmour, Jill Cox, Josephine H. Fast, Patricia Hayes, Peter Vardas, Eftyhia Williamson, Carolyn Gray, Clive M. PLoS One Research Article The genetic diversity of HIV-1 across the globe is a major challenge for developing an HIV vaccine. To facilitate immunogen design, it is important to characterize clusters of commonly targeted T-cell epitopes across different HIV clades. To address this, we examined 39 HIV-1 clade C infected individuals for IFN-γ Gag-specific T-cell responses using five sets of overlapping peptides, two sets matching clade C vaccine candidates derived from strains from South Africa and China, and three peptide sets corresponding to consensus clades A, B, and D sequences. The magnitude and breadth of T-cell responses against the two clade C peptide sets did not differ, however clade C peptides were preferentially recognized compared to the other peptide sets. A total of 84 peptides were recognized, of which 19 were exclusively from clade C, 8 exclusively from clade B, one peptide each from A and D and 17 were commonly recognized by clade A, B, C and D. The entropy of the exclusively recognized peptides was significantly higher than that of commonly recognized peptides (p = 0.0128) and the median peptide processing scores were significantly higher for the peptide variants recognized versus those not recognized (p = 0.0001). Consistent with these results, the predicted Major Histocompatibility Complex Class I IC(50) values were significantly lower for the recognized peptide variants compared to those not recognized in the ELISPOT assay (p<0.0001), suggesting that peptide variation between clades, resulting in lack of cross-clade recognition, has been shaped by host immune selection pressure. Overall, our study shows that clade C infected individuals recognize clade C peptides with greater frequency and higher magnitude than other clades, and that a selection of highly conserved epitope regions within Gag are commonly recognized and give rise to cross-clade reactivities. Public Library of Science 2011-10-12 /pmc/articles/PMC3192159/ /pubmed/22022524 http://dx.doi.org/10.1371/journal.pone.0026096 Text en Zembe et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zembe, Lycias Burgers, Wendy A. Jaspan, Heather B. Bekker, Linda-Gail Bredell, Helba Stevens, Gwynneth Gilmour, Jill Cox, Josephine H. Fast, Patricia Hayes, Peter Vardas, Eftyhia Williamson, Carolyn Gray, Clive M. Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials |
title | Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials |
title_full | Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials |
title_fullStr | Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials |
title_full_unstemmed | Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials |
title_short | Intra- and Inter-clade Cross-reactivity by HIV-1 Gag Specific T-Cells Reveals Exclusive and Commonly Targeted Regions: Implications for Current Vaccine Trials |
title_sort | intra- and inter-clade cross-reactivity by hiv-1 gag specific t-cells reveals exclusive and commonly targeted regions: implications for current vaccine trials |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3192159/ https://www.ncbi.nlm.nih.gov/pubmed/22022524 http://dx.doi.org/10.1371/journal.pone.0026096 |
work_keys_str_mv | AT zembelycias intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT burgerswendya intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT jaspanheatherb intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT bekkerlindagail intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT bredellhelba intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT stevensgwynneth intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT gilmourjill intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT coxjosephineh intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT fastpatricia intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT hayespeter intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT vardaseftyhia intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT williamsoncarolyn intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials AT grayclivem intraandintercladecrossreactivitybyhiv1gagspecifictcellsrevealsexclusiveandcommonlytargetedregionsimplicationsforcurrentvaccinetrials |